Based on these comments we herewith respond to all questions raised in a point-by-point manner, as follows: Reviewer 2 Major Issues:
[4] In Figures 3G and 3H, please specify p-values for untreated vs selumetinib in FLO-1/EV and OE33/shMACC1 respectively. If the difference is statistically significant, please briefly explain/speculate why.